← Back to Search

Communication Strategies for HPV Vaccination

N/A
Waitlist Available
Led By Noel T Brewer, PhD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial compares two ways to improve HPV vaccination communication in primary care. Clinics will receive training from outside expert or internal vaccine champion.

Who is the study for?
This trial is for primary care clinics that serve children aged 9-12, specializing in pediatrics or family medicine. Clinics will be enrolled and their staff trained to communicate about HPV vaccination; however, children won't be directly involved.
What is being tested?
The study compares two training methods aimed at improving HPV vaccine discussions: one delivered by an external expert and the other by a 'vaccine champion' from within the healthcare system itself.
What are the potential side effects?
Since this trial focuses on communication training rather than medical interventions, there are no direct side effects related to medications or vaccines being studied.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
HPV vaccination (≥1 dose), 9-12 year olds
Secondary study objectives
HPV vaccination (2 doses), 9-12 year olds

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Traditional AATExperimental Treatment1 Intervention
Staff in clinics randomized to this arm will also receive Announcement Approach Training (AAT). The training will be organized and delivered by outside experts.
Group II: Champion AATExperimental Treatment1 Intervention
Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT). This training is designed to improve communication about HPV vaccination. The training will be organized and delivered by vaccine champions from participating healthcare systems.

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
365 Previous Clinical Trials
92,680 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,112,047 Total Patients Enrolled
University of Wisconsin, MadisonOTHER
1,237 Previous Clinical Trials
3,200,939 Total Patients Enrolled
Noel T Brewer, PhDPrincipal InvestigatorUniversity of North Carolina
8 Previous Clinical Trials
5,568 Total Patients Enrolled

Media Library

Traditional AAT Clinical Trial Eligibility Overview. Trial Name: NCT05736718 — N/A
Human Papillomavirus Research Study Groups: Traditional AAT, Champion AAT
Human Papillomavirus Clinical Trial 2023: Traditional AAT Highlights & Side Effects. Trial Name: NCT05736718 — N/A
Traditional AAT 2023 Treatment Timeline for Medical Study. Trial Name: NCT05736718 — N/A
~9 spots leftby Jun 2025